All In Biotech

Drug Trial Radar · NCT06285279

The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases

Evaluation of the Safety and Efficacy of the BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases: A Single-center Exploratory Clinical Study

Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Mar 4, 2024

Primary completion

Dec 31, 2026

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Nanjing University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a single-center, open-label, dose-escalation exploratory clinical trial, expected to enroll 6 to 12 participants. It will use a BOIN (Bayesian Optimal Interval) design for dose escalation, with four predetermined dose groups (0.3×10\^6 cells/kg, 1.0×10\^6 cells/kg, 3.0×10\^6 cells/kg, and an alternative dose of 0.1×10\^6 cells/kg). Each dose group plans to enroll 1-2 or 3-6 participants with relapsed or refractory autoimmune-mediated kidney diseases (such as lupus nephritis, ANCA-associated vasculitis, membranous nephropathy, and IgG4-related diseases).

Conditions

  • Lupus Nephritis
  • ANCA-associated Vasculitis
  • Membranous Nephropathy - PLA2R Induced
  • IgG4-Related Diseases

Interventions

  • FKC289Drug

    The autologous dual target BCMA/CD19-CAR-T cell of this study is obtained by infecting T cells with anti-BCMA/CD19-CAR lentiviral vectors. Administration method: intravenous infusion; Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of subjects with dose-limiting toxicityTime frame: Within 28 days after the BCMA/CD19 dual targeted CAR-T cells injection infusion
  2. The proportion of subjects with adverse eventsTime frame: Within 24 weeks after the BCMA/CD19 dual targeted CAR-T cells injection infusion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jinling Hospital

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.